Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.75 EUR | -0.68% | +3.02% | -20.23% |
25/04 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
18/03 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Sales 2024 * | 59.72M 64.85M 5.4B | Sales 2025 * | 77.53M 84.2M 7.01B | Capitalization | 773M 839M 69.88B |
---|---|---|---|---|---|
Net income 2024 * | -14M -15.2M -1.27B | Net income 2025 * | 1M 1.09M 90.44M | EV / Sales 2024 * | 12.7 x |
Net cash position 2024 * | 15.17M 16.47M 1.37B | Net cash position 2025 * | 27.2M 29.54M 2.46B | EV / Sales 2025 * | 9.61 x |
P/E ratio 2024 * |
-51
x | P/E ratio 2025 * |
-1,458
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
0.56% | Free-Float | 42.17% |
1 week | +3.55% | ||
Current month | +7.10% | ||
1 month | +14.68% | ||
3 months | -17.61% | ||
6 months | -30.67% | ||
Current year | -21.31% |
Managers | Title | Age | Since |
---|---|---|---|
Stefan Glombitza
CEO | Chief Executive Officer | - | 01/16/01 |
Enno Spillner
DFI | Director of Finance/CFO | 55 | 01/23/01 |
Andreas Seidl
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olaf Stiller
FOU | Founder | 47 | 01/07/01 |
Peter Wendeln
BRD | Director/Board Member | 59 | - |
Klaus Röhrig
BRD | Director/Board Member | 47 | 10/20/10 |
Date | Price | Change |
---|---|---|
20/24/20 | 43.75 | -1.35% |
17/24/17 | 44.35 | +0.68% |
16/24/16 | 44.05 | -2.22% |
15/24/15 | 45.05 | +4.04% |
14/24/14 | 43.3 | +2.49% |
Delayed Quote Börse Stuttgart, May 21, 2024 at 01:25 am IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- FYB Stock
- FYB Stock